Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of...
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers.
Target Price
The average target price of PMN is 33 and suggests 29% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell